Menu Search
Equities

Amedisys Inc

AMED:DEU

Amedisys Inc

Actions
  • Price (EUR)89.00
  • Today's Change0.50 / 0.56%
  • Shares traded0.00
  • 1 Year change+1.71%
  • Beta--
Data delayed at least 15 minutes, as of Nov 08 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Amedisys Inc had net income fall from a gain of 118.61m to a loss of 9.75m despite flat revenues. A contributing factor has been an increase in the selling, general and administrative costs as a percentage of sales from 33.92% to 34.88%.
Gross margin43.67%
Net profit margin3.56%
Operating margin6.38%
Return on assets3.97%
Return on equity7.58%
Return on investment5.33%
More ▼

Cash flow in USDView more

In 2023, Amedisys Inc increased its cash reserves by 156.52%, or 84.73m. The company earned 137.19m from its operations for a Cash Flow Margin of 6.13%. In addition the company generated 35.06m cash from investing, though they paid out 87.52m more in financing than they received.
Cash flow per share3.28
Price/Cash flow per share29.35
Book value per share35.05
Tangible book value per share-6.00
More ▼

Balance sheet in USDView more

Amedisys Inc has a Debt to Total Capital ratio of 24.14%, a lower figure than the previous year's 35.28%.
Current ratio1.19
Quick ratio--
Total debt/total equity0.3327
Total debt/total capital0.2414
More ▼

Growth rates in USD

SmartText is unavailable
EPS growth(5 years)--
EPS (TTM) vs
TTM 1 year ago		3,307.12
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.